Swiss National Bank Lowers Stake in Roivant Sciences Ltd. $ROIV

Swiss National Bank cut its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 3.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 681,646 shares of the company’s stock after selling 23,500 shares during the period. Swiss National Bank owned about 0.10% of Roivant Sciences worth $7,682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of ROIV. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Roivant Sciences by 58.4% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 25,980 shares of the company’s stock worth $293,000 after buying an additional 9,580 shares during the period. Creative Planning lifted its position in shares of Roivant Sciences by 112.9% in the second quarter. Creative Planning now owns 52,539 shares of the company’s stock valued at $592,000 after acquiring an additional 27,863 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Roivant Sciences by 150.1% in the second quarter. SG Americas Securities LLC now owns 43,401 shares of the company’s stock worth $489,000 after acquiring an additional 26,050 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Roivant Sciences by 7.5% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 108,166 shares of the company’s stock worth $1,219,000 after purchasing an additional 7,531 shares in the last quarter. Finally, Tiff Advisory Services LLC purchased a new stake in shares of Roivant Sciences during the second quarter worth about $6,272,000. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on ROIV. Jefferies Financial Group boosted their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research report on Thursday, September 18th. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Finally, Citigroup increased their price objective on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $22.56.

Insiders Place Their Bets

In other news, Director Daniel Allen Gold sold 1,300,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the sale, the director directly owned 18,047,727 shares in the company, valued at $365,105,517.21. The trade was a 6.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Eric Venker sold 683,818 shares of the company’s stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $14.95, for a total transaction of $10,223,079.10. Following the sale, the chief executive officer owned 1,969,767 shares in the company, valued at $29,448,016.65. This represents a 25.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 8,483,561 shares of company stock valued at $143,557,750 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV opened at $20.82 on Friday. The stock has a market capitalization of $14.48 billion, a PE ratio of -37.17 and a beta of 1.23. The company’s fifty day moving average is $18.27 and its 200 day moving average is $14.01. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $21.35.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.